Home
HelpTest Code Billings Clinic: 9517 Mayo: CTX Beta-CrossLaps, Serum
Reporting Name
Beta-CrossLaps (B-CTx), SPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Useful For
Monitoring antiresorptive therapies (eg, bisphosphonates and hormone replacement therapy) in postmenopausal women treated for osteoporosis and individuals diagnosed with osteopenia
An adjunct in the diagnosis of medical conditions associated with increased bone turnover
Method Name
Electrochemiluminescence Immunoassay (ECLIA)
Specimen Required
Patient Preparation: Patient should fast for 12 hours before specimen collection.
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube:
Preferred: Red top
Acceptable: Serum gel
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions:
1. Collect specimen prior to 10 a.m.
2. Centrifuge and aliquot serum into plastic vial.
Specimen Type
SerumSpecimen Minimum Volume
0.75 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Serum | Frozen (preferred) | 90 days | |
| Refrigerated | 72 hours |
Reject Due To
| Gross hemolysis | Reject |
| Gross lipemia | OK |
| Gross icterus | Reject |
Reference Values
Males
<5 years: 242-1292 pg/mL
5-9 years: 351-1532 pg/mL
10-15 years: 447-2457 pg/mL
16-17 years: 478-1666 pg/mL
18-29 years: 238-1019 pg/mL
30-39 years: 225-936 pg/mL
40-49 years: 182-801 pg/mL
50-59 years: 161-737 pg/mL
60-69 years: 132-752 pg/mL
≥70 years: 118-776 pg/mL
Females
<5 years: 347-1508 pg/mL
5-9 years: 383-1556 pg/mL
10-15 years: 311-1776 pg/mL
16-17 years: 146-1266 pg/mL
18-29 years: 148-967 pg/mL
30-39 years: 150-635 pg/mL
40-49 years: 131-670 pg/mL
50-59 years: 183-1060 pg/mL
60-69 years: 171-970 pg/mL
≥70 years: 152-858 pg/mL
Premenopausal: 136-689 pg/mL
Postmenopausal: 177-1015 pg/mL
Interpretation
Elevated levels of beta-C-terminal telopeptide (CTx) indicate increased bone resorption. Increased levels are associated with osteoporosis, osteopenia, Paget disease, hyperthyroidism, and hyperparathyroidism.
In patients taking antiresorptive agents (bisphosphonates or hormone replacement therapy), a decrease of 25% or more from baseline beta-CTx levels (ie, prior to the start of therapy) 3 to 6 months after initiation of therapy indicates an adequate therapeutic response.
Day(s) Performed
Monday through Saturday
Report Available
1 to 3 daysTest Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
82523
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| CTX | Beta-CrossLaps (B-CTx), S | 41171-0 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| CTX | Beta-CrossLaps (B-CTx), S | 41171-0 |
Forms
If not ordering electronically, complete, print, and send a General Request (T239) with the specimen.